除了缓解疼痛之外:关于社区药房NSAID处方,多药和药物相互作用风险的跨部门研究
Javedh Shareef1, Sathvik Belagodu Sridhar1, Saeed Humaid Al Naqbi1
1Clinical Pharmacy & Pharmacology, Ras Al Khaimah College of Pharmacy, Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah 11172, United Arab Emirates.
Healthcare (Basel, Switzerland)
|December 30, 2025
概括
经常处方非类固醇抗炎药物 (NSAID) 与多种药物和潜在的药物相互作用 (pDDI) 有关. 这凸显了需要更安全的处方实践和药剂师监督,以提高患者安全.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
- 药品安全 药品安全
背景情况:
- 非类固醇抗炎药物 (NSAIDs) 是全球普遍用于治疗疼痛和炎症的药物.
- 多药性和潜在的药物相互作用 (pDDI) 对患者的安全构成风险,特别是在长期使用NSAID的情况下.
研究的目的:
- 分析社区药房NSAID处方模式.
- 评估拉斯阿尔开马的多药和pDDI的流行情况.
主要方法:
- 在社区药房进行了六个月的定量横截面研究.
- 评估NSAID处方的模式;使用Lexicomp识别的多药和pDDI.
- 统计分析包括奇平方测试和后勤回归.
主要成果:
- 在1865种药物中,908种NSAID被处方,在600种处方中总共处方了1865种药物.
- 切莱科西布和凯托是最常见的NSAIDs;阿司匹林和切莱科西布经常参与pDDI.
- 确定了357名pDDI,其国籍,并发症和药物数量预测了pDDI.
结论:
- 高度的NSAID处方,多药和pDDI需要基于证据的实践.
- 监管框架,药物使用政策和药剂师审查对于提高患者安全至关重要.
相关概念视频
Drug Dosing: Geriatric Patients
206
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
206
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
178
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
178
Pharmacodynamics in Geriatric Patients: Effects of Age
174
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
174
Pharmacokinetics: Drug–Drug Interactions
316
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
316
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
209
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
209
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
153
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
153


